Radically different
Stronger Together: A Path Towards an EU Mental Health Strategy for All is Mental Health Europe’s policy brief for the European Mental Health Week 2026
The post Policy Brief – Stronger Together: A Path Towards an EU Mental Health Strategy for All appeared first on Mental Health Europe.
For immediate release Stronger Together: A Path Towards a EU Mental Health Strategy For All This new policy brief warns that without governance, funding and accountability, three years of EU […]
The post Statement: Stronger Together: A Path Towards a EU Mental Health Strategy For All appeared first on Mental Health Europe.
The groundbreaking partnership that successfully treated a rare metabolic disorder in KJ Muldoon, or “Baby KJ,” with personalized CRISPR therapy last year has led therapy developers, researchers, and regulators, including the FDA, to craft a pathway for expanding the universe of gene therapies to advance the development of N-of-1 gene-editing therapies.
In February, the FDA unveiled its Plausible Mechanism Pathway draft guidance, a series of initiatives designed to increase regulatory flexibility and spur the development of bespoke gene-editing therapies for rare and ultra-rare disorders, which collectively total about 30 million individuals in the United States.
“The Agency anticipates that substantial evidence of effectiveness for individualized therapies could be established based on a single adequate and well-controlled clinical investigation with confirmatory evidence,” the draft guidance stated.
Last June, at a historic roundtable of cell and gene therapy researchers and clinicians hosted by the FDA, base editing pioneer David Liu, PhD, of Harvard University and the Broad Institute of MIT and Harvard, stated: “With sufficient organization and federal support and partnership with the FDA, I believe it will be possible by 2030 to treat at least 1,000 patients with personalized genetic treatments.”
Meanwhile, conventional gene therapy development continued in 2025. Last year saw four U.S. gene therapy approvals, bringing the number of FDA-approved gene and cell therapies up to 26, according to the American Society of Gene and Cell Therapies (ASGCT)—more than half of the 40 tallied by the organization as being approved worldwide.
Of those 26, 18 were gene therapies, of which 10 had disclosed sales high enough to be included on this A-List, which ranks top-selling gene therapies based on sales and net product revenue figures furnished by the companies in regulatory filings, annual reports, and/or press releases. Each gene therapy is listed with its sponsor(s), type, indication, and initial FDA approval date.
Not included are gene therapies with sales below the top 10, a category that includes two gene therapies approved in 2025: Precigen’s Papzimeos
(zopapogene imadenovec-drba), which generated $3.4 million in net product revenue last year after becoming the first-and-only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP) in August; and Abeona Therapeutics’ Zevaskyn® (prademagene zamikeracel), an autologous cell sheet-based gene therapy approved to treat wounds in adults and children with recessive dystrophic epidermolysis bullosa (RDEB).
Three gene therapies did not have disclosed sales in 2025, including:
(revakinagene taroretcel-lwey), an allogeneic encapsulated cell-based gene therapy marketed by Neurotech Pharmaceuticals and indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). (etuvetidigene autotemcel), a cell-based gene therapy and the first FDA-approved treatment for Wiskott-Aldrich syndrome (WAS). Developer Fondazione Telethon is the first non-profit organization to have successfully led full development of an ex vivo gene therapy from lab research (at Milan’s San Raffaele Telethon Institute for Gene Therapy or SR-Tiget) to regulatory approval.Also not included this year are sales of three gene therapies that had been marketed by Bluebird Bio: Beta thalassemia treatment Zynteglo (betibeglogene autotemcel), sickle cell disease treatment Lyfgenia® (lovotibeglogene autotemcel), and cerebral adrenoleukodystrophy (CALD) treatment Skysona® (elivaldogene autotemcel).
Last year, Bluebird Bio went private after being acquired by funds managed by Carlyle and SK Capital Partners, then rebranded in September as Genetix Biotherapeutics. Genetix does not disclose sales but did announce on March 2 that more than 100 patients received infusions of the three gene therapies during 2025.
Also last year, Pfizer halted development and commercialization of Beqvez (fidanacogene elaparvovec-dzkt), which had been co-marketed with Roche-owned Spark Therapeutics, after it generated no sales in 2024. Last August, Pfizer terminated its license agreement with Spark for Beqvez, an adeno-associated virus (AAV) vector-based gene therapy indicated for forms of moderate to severe hemophilia B in adults.
Top 10 Best Selling Gene Therapies |
|
1. Zolgensma® (onasemnogene abeparvovec-xioi) 2025 Sales: $1.232 billion 1 Sponsor(s): Novartis2 Type: AAV vector-based gene therapy Indication(s): Treatment of pediatric patients less than two years of age with spinal muscular atrophy (SMA) with biallelic mutations in the survival motor neuron 1 (SMN1) gene. Initial FDA Approval Date: May 24, 2019 |
|
2. Elevidys® (delandistrogene moxeparvovec-rokl) 2025 Sales: $898.7 million Sponsor(s): Sarepta Therapeutics Type: AAV vector-based gene therapy Indication(s): Treatment of ambulatory pediatric patients aged four through five years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.3 Initial FDA Approval Date: June 22, 2023 (Accelerated Approval) |
|
3. Vyjuvek® (beremagene geperpavec-svdt) 2025 Sales: $389.13 million Sponsor(s): Krystal Biotech Type: Herpes-simplex virus type 1 (HSV-1) vector-based gene therapy Indication(s): Treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. Initial FDA Approval Date: May 19, 2023 |
|
4. Adstiladrin® (nadofaragene firadenovec-vncg) 2025 Sales: €172.673 million ($199.329 million) Sponsor(s): Ferring Pharmaceuticals Type: Non-replicating adenoviral vector-based gene therapy Indication(s): Treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Initial FDA Approval Date: December 16, 2022 |
|
5. Casgevy® (exagamglogene autotemcel; “exa-cel”) 2025 Sales: $115.8 million Sponsor(s): Vertex Pharmaceuticals and CRISPR Therapeutics Type: Autologous genome-edited hematopoietic stem cell-based gene therapy Indication(s): Treatment of patients aged 12 years and older with sickle cell disease with recurrent vaso-occlusive crises (VOCs), or transfusion-dependent β-thalassemia (TDT). Initial FDA Approval Date: December 8, 2023 |
|
6. Hemgenix® (etranacogene dezaparvovec-drlb) 2025 Sales: A$92 million ($64.9 million)4 Sponsor(s): CSL Behring Type: AAV vector-based gene therapy Indication(s): Treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes. Initial FDA Approval Date: November 22, 2022 |
|
7. Kebilidi 2025 Sales: $56.626 million Sponsor(s): PTC Therapeutics Type: AAV vector-based gene therapy Indication(s): Treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Initial FDA Approval Date: November 13, 2024 |
|
8. Luxturna® (voretigene neparvovec-rzyl) 2025 Sales: CHF 41 million ($51.8 million) Sponsor(s): Spark Therapeutics (Roche) Type: Adeno-associated virus vector-based gene therapy Indication(s): Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s). Initial FDA Approval Date: December 18, 2017 |
|
9. Lenmeldy 2025 Sales: ¥6.4 billion ($40.2 million) Sponsor(s): Orchard Therapeutics (a wholly owned subsidiary of Kyowa Kirin) Type: Autologous hematopoietic stem cell-based gene therapy Indication(s): Treatment for children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ), or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD). Initial FDA Approval Date: March 18, 2024 |
|
10. Roctavian® (valoctocogene roxaparvovec-rvox; “val-rox”) 2025 Sales: $36 million Sponsor(s): BioMarin Pharmaceutical Type: AAV vector-based gene therapy Indication(s): Treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to AAV serotype 5 detected by an FDA-approved test. Initial FDA Approval Date: June 30, 2023 |
References
|
The post Top 10 Best Selling Gene Therapies appeared first on GEN – Genetic Engineering and Biotechnology News.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
Today, nuclear energy enjoys rare support across the political spectrum. Public approval has spiked, and Big Tech is throwing money around to meet rising electricity demand. That newfound interest is exactly why it’s time to talk about an old problem: nuclear waste.
In the US, nuclear reactors produce about 2,000 metric tons of high-level waste each year—and there’s nowhere to put it. Now, the need for a permanent storage solution is becoming urgent. Here’s what’s at stake.
—Casey Crownhart
This article is from The Spark, MIT Technology Review’s weekly climate newsletter. Sign up to receive it in your inbox every Wednesday.
When people say AI will transform industries, what they have in mind—whether they know it or not—are AI agents. ChatGPT showed AI can talk. But to change the world, it needs to do stuff.
The real power comes when agents work as teams, coordinating multiple roles to tackle complex tasks. Apps like Codex and Claude Cowork offer a glimpse of this shift, bringing multi-agent general-purpose productivity tools.
In theory, networks of AI agents could do to white-collar knowledge work what assembly lines did to manufacturing. That’s the vision. But as agents move into real-world systems, the risks grow too. Read the full story.
—Will Douglas Heaven
Agent Orchestration is one of the 10 Things That Matter in AI Right Now, MIT Technology Review’s guide to what’s really worth your attention in the busy, buzzy world of AI. We’re unpacking one item from the list each day here in The Download, so stay tuned.
In February 2019, a group of scientists proposed a high-risk, cutting-edge, irresistibly exciting idea that the National Science Foundation should fund: making “mirror” bacteria.
These lab-created microbes would be organized like ordinary bacteria, but their proteins and sugars would be mirror images of those found in nature. Researchers believed they could reveal new insights into building cells, designing drugs, and even the origins of life.
But now, many of them have reversed course. They’ve become convinced that mirror organisms could trigger a catastrophic event threatening every form of life on Earth. Find out why.
—Stephen Ornes
This is our latest story to be turned into an MIT Technology Review Narrated podcast, which we publish each week on Spotify and Apple Podcasts. Just navigate to MIT Technology Review Narrated on either platform, and follow us to get all our new content as it’s released.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 Elon Musk says Sam Altman “stole a charity” at the OpenAI trial
Musk testified for the first time yesterday in the landmark legal showdown. (FT $)
+ He said OpenAI was founded as a non-profit to avoid a “Terminator outcome.” (Wired $)
+ And claimed he came up with the idea for the company. (Reuters $)
+ The trial could upend the global AI race. (MIT Technology Review)
2 The White House has plans to bypass Anthropic’s blacklisting
It’s drafting guidance to sidestep the supply-chain risk designation. (Axios)
+ The White House is also meeting other tech firms to discuss AI risks. (Politico)
+ The Pentagon’s culture war against Anthropic has backfired. (MIT Technology Review)
3 OpenAI is tightening ties with Amazon after retreating from Microsoft
AWS customers are getting extra access to OpenAI systems. (NBC News)
+ While OpenAI gets new users and cloud-computing capabilities. (CNBC)
4 AI bots told scientists how to create biological weapons
And unleash them in public spaces. (NYT $)
+ AI will change war forever. (MIT Technology Review)
5 China has suspended robotaxi licenses after a scary outage
Dozens of Baidu vehicles suddenly stopped last month. (The Verge)
+ Chinese robotaxi firms are planning global expansions. (Guardian)
6 Meta has been found in breach of EU rules on protecting children
After failing to block access to Facebook and Instagram. (Guardian)
+ Parents are forcing schools to roll back classroom tech use. (NYT $)
7 AI is spotting pancreatic cancer years before symptoms appear
A study found it could catch the tumor early enough to treat. (Bloomberg)
8 The Iran war is disrupting data center rollouts
Oaktree-owned Pure DC is the latest firm to pause investments. (CNBC)
9 SpaceX is tying Elon Musk’s pay to Mars colonization goals
It’s set lofty goals for his jaw-dropping compensation. (Reuters $)
10 AI has reconstructed the face of an ancient Pompeii victim
Technology is reshaping our understanding of the distant past (NPR)
Quote of the day
—Elon Musk biographer Michel Martin tells NPR how the Tesla tycoon is shaping our lives.
One More Thing
If you’ve ever been through a large US airport, you’re probably aware of Clear, the identity verification service that uses biometric scans to whisk travelers past standard security checks.
Now Clear wants to expand that “face-first” experience from airports to just about everywhere, from retailers and banks to even your doctor’s office. Its CEO has designs on making Clear the “identity layer of the internet” and the “universal identity platform” of the physical world.
All you have to do is show up—and show your face. But as biometric identity systems go mainstream, concerns about privacy, security, and control are becoming harder to ignore. And the cost of convenience may not be shared equally. Discover what’s at stake.
—Eileen Guo
We can still have nice things
A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ Discover why the eight-hour night is a modern invention.
+ This artist creates masterpieces using only a vintage typewriter and a lot of patience.
+ Test your local knowledge with this game that drops you in a random Street View location.
+ Watch this incredible feat of precision piloting as a race aircraft touches down on a 120km/h cargo train.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
Elon Musk and OpenAI CEO Sam Altman head to trial this week in a case with sweeping consequences. Ahead of OpenAI’s IPO, the court could rule on whether the company can exist as a for-profit enterprise. It could even oust its leadership.
Musk, an OpenAI co-founder, claims he was deceived into bankrolling the firm under false pretenses. He’s seeking $134 billion in damages, the removal of Altman and president Greg Brockman, and the company’s restoration to a non-profit.
Find out how the trial could upend the global AI race.
—Michelle Kim
In a celebrated South Park episode, a community of gnomes sneak out at night to steal underpants. Why? The gnomes present their pitch deck. “Phase 1: Collect underpants. Phase 2: ? Phase 3: Profit.” It’s a business plan that captures the current state of AI.
Companies have built the tech (Step 1) and promised transformation (Step 3). But how they get there is still a big question mark. Read about the potential paths forward.
—Will Douglas Heaven
This story originally appeared in The Algorithm, our weekly newsletter giving you the inside track on all things AI. Sign up to receive it in your inbox every Monday.
For years, experts have warned that deepfakes could be deployed in malicious ways. These dangers are now here.
Cheap, accessible models now produce weaponized deepfakes—from sexually explicit images to political propaganda—that look startlingly real. They’re already inciting violence, changing minds, and sowing mistrust, with women and marginalized groups disproportionately affected.
Experts fear that they’re cratering trust and critical thinking. Here’s why they’re alarmed.
—Eileen Guo
Weaponized deepfakes are on our list of the 10 Things That Matter in AI Right Now, MIT Technology Review’s guide to what’s really worth your attention in the busy, buzzy world of AI.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 OpenAI has ended its exclusive partnership with Microsoft
The new deal allows OpenAI to court rivals such as Amazon. (Reuters $)
+ Microsoft will still license OpenAI’s tech, but no longer exclusively. (NYT $)
+ OpenAI is missing key growth targets ahead of its IPO. (WSJ $)
2 Google has signed a classified AI deal with the Pentagon
It permits AI use for “any lawful government purpose.” (The Information $)
+ Over 600 Google workers had called for a block on the deal. (QZ)
+ AI firms are set to train military versions of their models on classified data. (MIT Technology Review)
3 The EU has told Google to open Android to AI rivals
It wants to end Gemini’s built-in advantage. (Ars Technica)
+ Google calls the move an “unwarranted intervention.” (WSJ $)
+ A final decision is expected by the end of July. (Reuters $)
4 OpenAI is reportedly developing an AI-first smartphone
It would replace apps with agents. (TechCrunch)
+ Qualcomm and MediaTek may be developing its processors. (Gizmodo)
5 A brain implant for depression is moving into human testing
The FDA has approved a human study of the device. (Wired $)
+ BCIs have thus far struggled to reach the market. (MIT Technology Review)
6 A populist backlash against AI is gaining momentum in rural America
From Indiana to Idaho, voters are pushing back against the technology. (NYT $)
+ Anti-AI protests are expanding worldwide. (MIT Technology Review)
7 DeepSeek has priced its new model 97% below OpenAI’s GPT-5.5
It aims to attract more enterprises, developers, and agent-based users. (SCMP)
+ Here are three reasons why DeepSeek V4 matters. (MIT Technology Review)
8 AI now generates a third of new websites
A study found it’s making the web more cheery and less verbose. (404 Media)
9 Top talent is leaving Big Tech to launch their own AI startups
Meta, Google, and OpenAI are facing a brain drain. (CNBC)
10 Taylor Swift is trademarking her voice and image
The Grammy winner has been the target of numerous deepfakes. (NBC News)
+ A growing number of celebrities are fighting AI with trademarks. (BBC)
Quote of the day
—Judge Yvonne Gonzalez Rogers reacts to prospective jurors confessing their negative views of Elon Musk ahead of his legal battle with Sam Altman, The Verge reports.
One More Thing
When Joe Rogan falsely declared that “party drugs” were an “important factor in AIDS,” several million people were listening. He also asserted that AZT, the earliest drug used to treat AIDS, killed people “quicker” than the disease itself—another claim that has been disproven.
Such comments illustrate an unmistakable resurgence in AIDS denialism: a false collection of theories arguing either that HIV does not cause AIDS or that there is no such thing as HIV at all. By the dawn of the millennium, these claims had largely fallen out of favour. That changed when the coronavirus arrived.
Follow the digital path from Covid skepticism to the return of a deadly conspiracy theory.
—Anna Merlan
We can still have nice things
A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ Explore the planets from your laptop with this live sky map.
+ This marathon DJ set from Daphni is an incredible journey through electronic music.
+ NASA’s stunning Artemis II wallpapers bring a high-res piece of deep space to your phone.
+ This fascinating GPS explainer breaks down how your phone figures out exactly where you are.
Sun Pharmaceutical Industries has agreed to acquire Organon, the women’s health drug developer spun out of Merck & Co., for $11.75 billion in a deal intended to catapult the buyer into a top 25 global biopharma—top three in women’s health—by growing its innovative medicines business and expanding its product offerings into biosimilar drugs, the companies said today.
Headquartered in Jersey City, NJ, Organon was spun out of Merck in 2021 and has since then grown its portfolio to more than 70 women’s health and general medicines products, including biosimilars, that have been commercialized in the U.S. and some 140 countries worldwide. In addition to the U.S., Organon’s largest markets include Brazil, Canada, China, and the countries of the European Union. Organon said it has six manufacturing facilities across the EU and emerging markets.
Sun Pharma said the combined company created by the deal will have annual revenue of $12.4 billion, a figure the company said would propel it into a top 25 global pharma—though the company was ranked No. 14 in GEN’s most recent A-List of Top 25 Biotech Companies Heading Into 2026, compiled last December, based on its market capitalization (share price times the number of outstanding shares) of INR 4.31 trillion ($50.8 billion).
Sun Pharma said Organon’s portfolio was similar to its own, and that the acquisition of Organon was aligned with its strategies of growing its Innovative Medicines business (to a 27% revenue share) and expanding into biosimilars as a Top 10 global company.
The combined company, Sun Pharma and Organon said, would be top three in global women’s health, creating a commercial platform for future growth; the seventh largest global biosimilar player; and a presence in 150 countries worldwide, with 18 large markets that would each generate more than $100 million in revenues.
“This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives,” Sun Pharma executive chairman Dilip Shanghvi said in a statement. “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long‑term growth.”
The deal ends two weeks of speculation that began with an April 10 report in the Indian news outlet The Economic Times stating that Sun Pharma had submitted a $12 billion all-cash offer for Organon. On Friday, the news outlet followed up with a report stating that Sun Pharma had submitted a revised $13 billion offer.
Investors appeared to support the deal, as Sun Pharma shares on India’s National Stock Exchange rose about 7% to INR 1,733.50 ($18.41) at the close of trading today.
Sun Pharma has agreed to acquire 100% of Organon’s issued and outstanding shares for cash. Sun said it planned to fund the acquisition through a combination of available cash resources and committed financing from banks.
“Together, we will become a partner of choice for acquiring and launching new products,” stated Kirti Ganorkar, managing director of Sun Pharma. “Our immediate priorities will be business continuity, disciplined integration, and responsible value creation. We see strong potential in leveraging Organon’s talent pool. In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years.”
Those synergies were later quantified by Sun Pharma as approximately $350 million within two to four years of the deal’s completion.
Sun Pharma did say, however, that the acquisition of Organon will strengthen its generation of cash, with its earnings before interest, taxes, depreciation, and amortization (EBITDA) and cash flow set to nearly double, supporting future efforts to reduce the net debt/EBITDA of 2.3x resulting from the deal.
Sun Pharma finished the first nine months of its fiscal year ending March 31, 2026, with a net profit of INR 87.654 billion ($931.5 million) and EBITDA of INR 137.772 billion ($1.464 billion; up 19.2% from the year-ago period), on sales of INR 436.604 billion ($4.64 billion), up 11.3% year over year.
During its fiscal year ending March 31, 2025, Sun Pharma reported adjusted net profit (excluding one-time items) of INR 119.844 billion ($1.274 billion), up 19% from a year earlier, on sales of INR 520.412 billion (about $5.53 billion). Reported net profit for FY 2025 was INR 109.290 billion ($1.161 billion), vs. Rs. 95.764 billion ($1.017 billion) during FY 2024.
Organon finished last year with adjusted EBITDA of $1.9 billion on revenue of $6.2 billion. The company reported debt of $8.64 billion—down from the $9.5 billion in debt it reported when it separated from Merck—and a cash balance of $574 million.
In November, Organon announced plans to sell its JADA® System, designed to control and treat abnormal postpartum uterine bleeding or hemorrhage, to Laborie Medical Technologies for up to $465 million—$440 million to be paid at closing, subject to adjustments, and up to $25 million tied to achieving 2026 revenue targets. Net proceeds from the divestiture will contribute to Organon’s cash balance as of March 31, 2026.
Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The transaction is expected to close in early 2027 subject to customary conditions, including regulatory approvals and Organon stockholder approval.
The boards of both Sun Pharma and Organon have approved the deal.
“Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders,” stated Carrie Cox, executive chair of Organon. “We believe Sun Pharma is well positioned to support Organon’s businesses, employees, and patients globally, and to further advance our commitment to delivering impactful medicines and solutions.”
The post Sun Pharma Aims for Top 3 in Women’s Health with $11.75B Organon Purchase appeared first on GEN – Genetic Engineering and Biotechnology News.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
In February 2019, a group of scientists proposed a high-risk, cutting-edge, irresistibly exciting idea that the National Science Foundation should fund: making “mirror” bacteria.
These lab-created microbes would be organized like ordinary bacteria, but their proteins and sugars would be mirror images of those found in nature. Researchers believed they could reveal new insights into building cells, designing drugs, and even the origins of life.
But now, many of them have reversed course. They’ve become convinced that mirror organisms could trigger a catastrophic event threatening every form of life on Earth. Find out why they’re ringing alarm bells.
—Stephen Ornes
This story is from the next issue of our print magazine, which is all about nature. Subscribe now to read it when it lands this Wednesday.
Earlier this month, a GitHub project called Colleague Skill struck a nerve by claiming to “distill” a worker’s skills and personality—and replicate them with an AI agent. Though the project was a spoof, it prompted a wave of soul-searching among otherwise enthusiastic early adopters.
A number of tech workers told MIT Technology Review that their bosses are already encouraging them to document their workflows for automation via tools like OpenClaw. Many now fear that they are being flattened into code and losing their professional identity.
In response, some are fighting back with tools designed to sabotage the automation process.
—Caiwei Chen
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 The White House and Anthropic are working toward a compromise
The Trump administration says they had a “productive meeting.” (Reuters $)
+ Trump had ordered US agencies to phase out Anthropic’s tech. (Guardian)
+ Despite the blacklist, the NSA is using Anthropic’s new Mythos model. (Axios)
2 Palantir has unveiled a manifesto calling for universal national service
While denouncing inclusivity and “regressive” cultures. (TechCrunch)
+ It’s a summary of CEO Alex Karp’s book “The Technological Republic.” (Engadget)
+ One critic called the book “a piece of corporate sales material.“ (Bloomberg $)
3 Germany’s chancellor and largest company want looser AI rules
Chancellor Merz said industrial AI needs more regulatory freedom. (Reuters $)
+ Siemens says it plans to shift investments to the US if EU rules don’t change. (Bloomberg $)
+ Fractures over AI regulation are also emerging in the US. (MIT Technology Review)
4 Nvidia’s once-tight bond with gamers is cracking over AI
Consumer graphics cards are no longer the priority. (CNBC)
+ But generative AI could reinvent what it means to play. (MIT Technology Review)
5 Insurers are trying to exclude AI-related harms from their coverage
And escape legal liability for AI’s mistakes. (FT $)
+ AI images are being used in insurance scams. (BBC)
6 AI is about to make the global e-waste crisis much worse
And most of the trash will end up in non-Western countries. (Rest of World)
+ Here’s what we can do about it. (MIT Technology Review)
7 Tinder and Zoom have partnered with Sam Altman’s eye-scanning firm
To offer a “proof of humanity” badge to users. (BBC)
8 Islamist insurgents in West Africa are driving surging demand for drones
A Nigerian UAV startup is opening its first factory abroad in Ghana. (Bloomberg $)
9 Hundreds of fake pro-Trump AI influencers are flooding social media
In an apparent bid to hook conservative voters. (NYT)
10 A Chinese humanoid has smashed the human half-marathon record
Despite crashing into a railing near the end of the race. (NBC News)
+ Chinese tech firm Honor swept the podium spots. (Engadget)
+ Last year, humans won the race by a mile. (CNN)
Quote of the day
—Ben Cumming, head of communications at the AI safety nonprofit Future of Life Institute, tells the Washington Post that diverse public figures are endorsing a declaration of AI policy priorities.
One More Thing
The International Space Station will be decommissioned as soon as 2030, but the story of America in low Earth orbit (LEO) will continue.
Using lessons from the ISS, NASA has partnered with private companies to develop new commercial space stations for research, manufacturing, and tourism. If they are successful, these businesses will bring about a new era of space exploration: private rockets flying to private destinations.
They will also demonstrate a new model in which NASA builds infrastructure and the private sector takes it from there—freeing the agency to explore deeper and deeper into space. Read the full story.
—David W. Brown
We can still have nice things
A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ Bask in thisadorable test of a dog’s devotion.
+ This vocal pitch trainer improves your singing straight from your browser.
+ Master international etiquette with this interactive guide to the world’s cultures.
+ Explore the networks of public figures with this intriguing interactive graph.
Finnish deep-tech startup, Proteins.1, launched with €4.7 million in pre-seed funding, led by Lifeline Ventures and Cloudberry Ventures, with in-kind support from VTT and Business Finland. Harnessing technology transferred from VTT Technical Research Centre of Finland, Proteins.1 is developing a PCR-like enzyme-free, ultra-sensitive amplification platform for the detection of proteins at the single-molecule level. The firm says it aims to transform early disease diagnostics by enabling detection of disease-related molecular warning signals long before there are clinical signs.
While polymerase chain reaction (PCR) technology has transformed modern diagnostics by allowing tiny amounts of DNA to be amplified into detectable signals, no equivalent amplification method has existed for proteins, which often signal the earliest onset of cancer, neurodegeneration, cardiovascular disease, and inflammatory conditions, the company notes. Proteins.1 aims to leverage its technology to establish a new category of ultra-sensitive protein diagnostics, combining high multiplexing, scalable chip-based detection, and significantly lower capital costs compared to existing systems.
The patented, physics-based technology introduces cyclic signal amplification for proteins, potentially enabling up to 1,000 times better sensitivity than current gold-standard platforms, Proteins.1 claims. Unlike conventional immunoassays that rely on enzymatic reactions prone to variability and noise, the Proteins.1 approach is solid-state, enzyme-free, and compatible with semiconductor-based photonic detection.
The platform replaces enzymatic signal amplification with a physics-based magnetic cycling mechanism that repeatedly reads a single captured protein molecule, accumulating signal clarity without increasing background noise. The company says this supports ultra-high sensitivity combined with high multiplexing, potentially enabling the simultaneous measurement of hundreds of biomarkers from a few drops of blood.
“For decades, diagnostics has been limited not by biology, but by what our instruments can detect,” commented Proteins.1 co-founder and CEO Prateek Singh, who is inventor of the core technology. “The body produces early warning signals long before disease becomes visible. Our mission is to make those signals measurable and actionable, years earlier than today.”
Built on research conducted at VTT and further validated through European Union breakthrough innovation funding, the technology has been granted U.S. and Finnish patents, and additional international applications are pending. Initially, the company aims to develop research-use-only applications in oncology, neurology, and immunology, before progressing toward regulated clinical diagnostics. “Early detection dramatically improves survival rates in diseases such as cancer and neurodegenerative disorders,” Singh continued. “If we can detect disease at the molecular stage rather than the symptomatic stage, we entirely change treatment possibilities.”
Proteins.1 plans to expand its engineering and product development team in Finland during 2026–2027, positioning itself as a European hub for next-generation diagnostic technology. “Proteins.1 represents the kind of deep scientific breakthrough that can redefine an entire industry,” said Jyri Engeström at Lifeline Ventures. “The team combines world-class research with proven experience in building and scaling regulated medtech businesses.” Cloudberry Ventures further highlighted the company’s strong alignment with European strengths in photonics, microfabrication, and precision engineering.
Added Rene Kromhof, at Cloudberry VC, “What sets Proteins.1 apart is a fundamentally new sensing approach. Rather than using enzymes that give you one chance to detect a protein, they use light and thin-film transistors to amplify the signal from a single protein until it rises above the noise. That dramatically improves sensitivity, and ultimately, how early disease can be caught.”
CEO Prateek Singh has previously raised venture capital for microfluidics ventures and holds multiple patent families. Co-founder and COO Harri Hallila previously built and exited a regulated medical device company. The broader team includes commercial leadership with experience in leading diagnostics platforms.
The post Proteins.1 Launches to Develop Single Molecule Protein Amplification Tech for Diagnostics appeared first on GEN – Genetic Engineering and Biotechnology News.
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
Inside a money-laundering center in Cambodia, an employee opens a banking app on his phone. It asks for a photo linked to the account, so he uploads a picture of a 30-something Asian man.
The app then requests a video “liveness” check. The scammer holds up a static image of a woman who doesn’t match the account. After 90 seconds, he’s in.
The exploit relies on illicit hacking services sold on Telegram that break “Know Your Customer” (KYC) facial scans. MIT Technology Review found 22 channels and groups advertising these services. This is what we discovered.
—Fiona Kelliher
—Casey Crownhart
Last week, news emerged that Microsoft was pausing carbon removal purchases. It was a bombshell—Microsoft effectively is the carbon removal market, single-handedly purchasing around 80% of all contracted carbon removal.
The report sparked fear across the industry, raising questions about the future of carbon removal and the role of Big Tech. Read the full story.
This story is from The Spark, our weekly newsletter exploring the technology that could combat the climate crisis. Sign up to receive it in your inbox every Wednesday.
—Emma Marris
Humans have done some destructive things to the ecosystems around us. But conservationists are learning that we can also be a force for good.
To understand how we work best with nature, a group of scientists, authors, and philosophers have developed new measurements of human-nonhuman relationships. Now, a team in the United Nations is continuing the work. Find out why—and what they hope to achieve.
This story is from the next issue of our print magazine, which is all about nature. Subscribe now to read it when it lands on Wednesday, April 22.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 Ukraine says Russian troops have surrendered to robots
They claim a fully automated attack captured army positions for the first time in history. (404 Media)
+ Europe’s vision for future wars is full of drones. (MIT Technology Review)
2 Monkeys with BCIs are navigating virtual worlds using only their thoughts
The research could help people with paralysis. (New Scientist)
+ But these implants still face a critical test. (MIT Technology Review)
3 NASA wants to put nuclear reactors on the Moon
They could power lunar bases and extend spaceflight. (Wired $)
+ NASA is also building a nuclear-powered spacecraft. (MIT Technology Review)
4 Plans for online age verification in the US are raising red flags
Experts warn of compliance issues and potential data breaches. (NBC News)
+ In the EU, an age verification app is about to launch. (Reuters $)
5 An AI chip boom just pushed Taiwan’s stock market past the UK’s
It’s risen past $4 trillion to become the world’s seventh largest. (FT $)
+ Future AI chips could be built on glass. (MIT Technology Review)
6 The public backlash against data centers is intensifying in the US
Protests and litigation are blocking projects. (CNBC)
+ One potential solution? Putting them in space. (MIT Technology Review)
7 Five-minute EV charging is becoming a reality
China’s BYD has started rolling it out. (Gizmodo)
+ “Extended-range electric vehicles” are about to hit US streets. (Atlantic $)
8 Stealth signals are bypassing Iran’s internet blackout
Files hidden in satellite TV broadcasts keep information flowing. (IEEE)
9 Shoe brand Allbirds made a shock pivot to AI, sending stock up 700%
No bubble to see here, folks. (CNBC)
+ What even is the AI bubble? (MIT Technology Review)
10 The largest ever map of the universe is complete
It captures 47 million galaxies and quasars. (Space.com)
Quote of the day
—Sylvia Whitt, a 78-year-old retiree based in Virginia, tells the Washington Post why they’re protesting against data centers.
One More Thing
Some Republican lawmakers want to criminalize porn and arrest its creators. But what if porn is wholly created by an algorithm? In that case, whether it’s obscene, ethical, or safe becomes a secondary issue. The primary concern will be what it means for porn to be “real”—and what the answer demands from all of us.
Technological advances could even remove the “messy humanity” from sex itself. The rise of AI-generated porn may be a symptom of a new synthetic sexuality, not the cause. Read the full story.
—Leo Herrera
We can still have nice things
A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ An animator turned his son’s drawings into epic anime characters.
+ Hundreds of baby green sea turtles made a spectacular first journey to the ocean.
+ You can now track rocket launches from take-off to orbit in real time.
+ These musical mistakes prove that even the classics aren’t perfect.
